Decision to list Interventional Radiology products supplied by Endotherapeutics New Zealand Limited, Terumo Australia PTY Limited and Boston Scientific New Zealand Limited
31 July 2018
What we are doing
We’re pleased to announce the approval of a listing agreement for Interventional Radiology products with Endotherapeutics New Zealand Limited (trading as Endoventure) (“Endoventure”), Terumo Australia PTY Limited (“Terumo”) and Boston Scientific New Zealand Limited (“Boston”).
In summary this will result in:
- 137 Interventional Radiology products from Endoventure being listed in Part III of Section H of the Pharmaceutical Schedule from 1 September 2018.
- 135 Interventional Radiology products from Terumo being listed in Part III of Section H of the Pharmaceutical Schedule from 1 September 2018.
- 1867 Interventional Radiology products from Boston being listed in Part III of Section H of the Pharmaceutical Schedule from 1 September 2018.
This Agreement would supersede any existing DHB contracts with these suppliers for the devices listed in Schedule One of the Agreement.
Any changes to the original proposal?
No changes were made to the listing agreement as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff:
- Interventional radiology staff
- Procurement officers
Detail about this decision
In September 2017 PHARMAC issued a request for proposals (“RFP”) for Interventional Radiology Products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After completing the RFP evaluation, and consulting on the provisional agreements reached with Endoventure, Boston and Terumo, PHARMAC has decided to list Endoventure, Boston and Terumo’s ranges of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 September 2018.
DHBs that purchase Endoventure, Boston and Terumo’s Interventional Radiology Products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 September 2018.
DHBs can continue to choose which Interventional Radiology Products they purchase.
Endoventure, Boston and Terumo’s products are the most recent Interventional Radiology products that PHARMAC has decided to list on the Pharmaceutical Schedule. Further consultations in this category are expected over the next few months.
Our response to what you told us
We’re really grateful for the time people took to respond to this consultation. A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
PHARMAC Staff Comment
Concern with impact of freight charges for Southern DHB
Freight removed from one line item that was particularly of concern
Advising that no technical or resource impacts are anticipated as a result of Endoventure, Boston and Terumo’s proposals
If you have any questions about this decision, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 July 2020